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The development of clinically useful histone deacetylase inhibitors has expanded greatly. In a preclinical
study, we showed that panobinostat (LBH589) inhibits cell cycle progression of human head and neck
squamous cell carcinoma (HNSCC) cell lines at G2/M and an associated decrease in expression of particular
genes required for passage through G2 and mitosis. In this study we sought to analyse the mechanistic
underpinnings of panobinostat-induced growth arrest. HNSCC cell lines were synchronised and
progression through mitosis monitored. We demonstrate that panobinostat causes a marked G2 delay and
mitotic defects. A loss of G2-specific Plk1 and Cyclin B1 expression and co-incident increase in p21Waf1/Cip1
expression is also shown. Furthermore, we show a significant loss of E2F1 recruitment to the promoters of
these genes in response to panobinostat treatment. These data provide mechanistic evidence of
panobinostat-induced cell cycle arrest and highlight its potential as a chemotherapeutic agent for HNSCC.
S
quamous cell carcinoma of the head and neck (HNSCC) is a disease of considerable morbidity and
mortality with an estimated 560,000 cases per year and 300,000 deaths worldwide, and approximately
50,000 new cases and 11,000 deaths in the United States annually1,2. HNSCC occur in the upper aero-
digestive tract from the nasopharynx and oral cavity to the larynx with varyingmetastatic rates for each anatomic
site. Treatment depends upon the disease location, the extent of the primary tumour and the presence of
metastatic disease. Conventional treatment usually includes surgery and adjuvant radiation therapy, with or
without chemotherapy. Any of these therapies can, and do, produce morbidities affecting speech, swallowing and
overall quality of life. Despite these interventions, recurrence of the disease is observed in about 50% of patients
with high rates of associated mortality3. Even though there has been only a modest improvement in overall
survival over the past decades, it has been questioned whether a large percentage of patients are over-treated,
incurring additional morbidity2. Therefore, strategies must be developed for the most appropriate treatment for
any given patient and new treatment paradigms need to be defined.
Histone deacetylases (HDACs) are a group of enzymes that remove acetyl groups from histone proteins,
thereby compacting chromatin and silencing the expression of genes. There are now 18 known HDACs grouped
into four classes, which can also deacetylate numerous non-histone target proteins and alter their function.
Indeed, some HDACs have been shown to alter the transcriptional activity of proteins such as p53, E2F and c-
Myc4–6. HDAC inhibition is generally thought to increase the expression of repressed genes, including tumor
suppressor genes, causing dramatic effects on cell growth and survival and because of this normal cells may be
ten-fold or more resistant to HDAC inhibitor (HDACi) induced cell death than transformed cells7. The isolation
of potent HDAC inhibitors (HDACi) has been the focus of numerous anti-cancer drug discovery efforts and the
testing and development of clinically useful HDACi via clinical trials has expanded greatly. Some of these drugs
inhibit selective classes of HDACs and some, like panobinostat (LBH589), a member of the hydroxamate class,
inhibit multiple HDAC classes7.
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Panobinostat has been shown to be effective in the treatment of
hematologic malignancies such as Hodgkin lymphoma, multiple
myeloma and cutaneous T-cell lymphoma8–12 and its use has also
been tested for the treatment of epithelial neoplasms either alone or
in combination with other chemotherapeutic agents13–19.While these
are very early clinical trials, some of the initial results are promising.
In a preclinical study, we showed that panobinostat inhibits cell cycle
progression of human HNSCC cell lines ultimately resulting in cell
death in vitro20. The cell cycle arrest occurred at G2/M and has been
observed in other studies using a variety of cell types including the
prostate cancer cell lines, PC3 and PC9 and an epithelial lung cancer
cell line A54921,22. In our study, we showed that the G2/M arrest was
associated with a substantial decrease in the expression of a particular
sub-set of genes that are required for the passage through the G2
checkpoint and into mitosis20. The objectives of the present study
were to define more specifically the cell cycle arrest caused by pano-
binostat and to elucidate the mechanistic underpinnings.
Results
Previously we showed that panobinostat results in a significant arrest
of the cells at G2/Mwithin 12 h post treatment20. To characterise this
arrest further and study potential defects in DNA replication, cells
were synchronised by double thymidine block and released into
medium containing 100 nM panobinostat or excipient control. At
0 h, cells are synchronised at the G1/S boundary (figure 1A). Control
treated cells progressed into S phase 4 h post release and passaged
through G2/M and into G1 phase by 8 h. By 12 h, the majority of the
cells had passed through mitosis and entered G1 phase. Cells subse-
quently re-entered S phase (20.5 h), showing completion of one cell
cycle. Cells released into 100 nM panobinostat entered and passed
through S phase with similar kinetics as the control cell population,
but in contrast to control cells, displayed a significant and prolonged
G2/M arrest at 8 and 12 h post release (figure 1A and B). By 20.5 h,
some cells remained arrested at G2/M but entry into G1 phase was
apparent, suggesting that treatment with panobinostat induces a
prolonged cell cycle delay, but not a complete arrest. Similar effects
of panobinostat on cell cycle progression were observed in UMSCC-
1 and UMSCC-47 cells (oral cavity, obtained from Dr. Thomas
Carey, University of Michigan23), with a significant increase in G2/
M cells 11.5 hours post release into medium containing 100 nM
panobinostat compared to cells released into control medium
(11.5% (p 5 0.02) and 21.7% (p 5 0.0006) increase in the G2/M
fraction in UM-SCC-1 and UMSCC-47 cells, respectively). To sup-
port the notion that this increase is due to a G2 arrest, a significant
decrease in G1 entry was also observed with this experiment (12.4%
(p 5 0.009) and 19.1% (p 5 0.01) decrease in G1 fraction on
UMSCC-1 and UMSCC-47 cells, respectively). These data provide
evidence that the cell cycle arrest caused by panobinostat treatment is
not cell type specific (supplementary figure 1).
To determine whether the cells were delayed at G2 phase or in
mitosis, phosphorylation of histone H3 (Serine 10) was assessed
(figure 1C). Histone H3 phosphorylation in control treated cells
peaked at around 9% at 9 h and quickly fell to below 3% by 12 h,
indicating mitotic entry and exit between 8 and 12 h post release
(figure 1D). In contrast, panobinostat-treated cells displayed a delay
in mitotic entry, reaching a peak of only 4.5% phosphorylated his-
tone H3 at 12 h, 4 h later than the control population. This strongly
suggests that panobinostat results in a significant delay at G2 phase
and reduced mitotic entry.
To confirm these data, we prepared metaphase spreads of syn-
chronised cells at various times post release (figure 2A). The number
of metaphases present in the control population peaked at 9 h
(11.5%)while cells cultured in 100 nMpanobinostat showed a highly
significant reduction inmetaphase cells (p, 0.0001), confirming the
reduced mitotic entry observed by histone H3 phosphorylation.
Although there is reduced entry into mitosis in cells treated with
panobinostat, some cells clearly enter mitosis. We therefore sought
to determine whether mitosis progressed normally in panobinostat-
treated cells. Synchronised cells were fixed 9 h post release, and the
mitotic spindles and DNA stained (figure 2B). The results confirmed
reduced mitotic entry (Figure 2C; 10% compared to 20% in control-
treated cells, p, 0.01). In addition, the percentage of the totalmitotic
cells in pre-anaphase (prophase and metaphase) was significantly
increased by nearly three fold following panobinostat treatment
(figure 2D; 87.5% compared to 32% in control cells, p, 0.002), with
a concomitant decrease in the percentage of mitotic cells in late stage
mitosis (anaphase and telophase, p , 0.001). Many mitotic cells at
metaphase had non-aligned chromosomes, where cells had appeared
to form a normal bipolar spindle but the chromosomes had not
congressed to the metaphase plate (3.5% in control cells compared
to 46% in panobinostat treated cells p, 0.001). In the few cells that
were found to have progressed into anaphase, many had lagging
chromosomes (12.5%, compared to 0% in control cells) although
this was not statistically significant (p 5 0.2), likely because very
few cells are able to progress into anaphase.
To visualize the G2 delay and mitotic failure, we imaged live cells
by timelapse microscopy to observe the progression of panobinostat
treated cells into and through mitosis (figure 3 and supplementary
movies 1 and 2).While synchronised control cells entered mitosis 8–
9 h post release and cells successfully completed mitosis within 1–
2 h, panobinostat-treated cells had far fewer successful mitoses (one
indicated by arrow (a) in the field), and some cells appeared to enter
mitosis (arrow (b)) but remain rounded, for over 10 h in this case,
and failed to complete mitosis.
Our previous report showed that panobinostat causes a dramatic
reduction in genes required for cell cycle progression including Polo-
like kinase 1 (PLK1)20. We therefore hypothesised that the mitotic
abnormalities observed are due to a loss of cell cycle dependent Plk1
expression. To test this, RNA and protein were prepared from syn-
chronised cells cultured in the presence or absence of panobinostat
for 2, 4, 8 and 12 h post release. Plk1 mRNA and protein expression
dramatically increased by 8 h post release in control cells, however
no significant increase in PLK1 mRNA or protein was observed in
panobinostat-treated cells (figure 4). In addition, microarray analysis
of gene expression in synchronised FaDu cells released for 8 h in
panobinostat or excipient control revealed a significant reduction in
the expression of Cyclin B1 mRNA (data not shown). More careful
analysis of Cyclin B1 mRNA and protein expression showed an
increase in expression between 4 and 8 h post release in control cells,
concomitant withmitotic entry, but a loss of cell cycle dependent up-
regulation in panobinostat-treated cells (figure 5). The loss of cell
cycle dependent upregulation of Plk1 and Cyclin B1 protein express-
ion was also assessed in two further oropharyngeal squamous cell
carcinoma cell lines (UMSCC-1 and UMSCC-47; supplementary
figures 2 and 3), confirming that these effects of panobinostat treat-
ment are not specific to FaDu cells.
Panobinostat, like many HDACi, results in a rapid and significant
increase in p21Waf1/Cip1 protein expression24. Furthermore, p21Waf1/Cip1
overexpression inhibits the transcription of PLK1, mediated by the
cell cycle-dependent element (CDE) and cell cycle genes homology
region (CHR)within the Plk1 promoter25,26. Cyclin B1 expression has
also been shown to be regulated by p21Waf1/Cip127. We therefore
hypothesized that the loss of cell cycle dependent PLK1 and Cyclin
B1 expression in panobinostat treated cells was due to panobinostat-
induced increase in p21Waf1/Cip1 expression prior to mitotic entry.
p21Waf1/Cip1 RNA and protein levels following panobinostat treatment
of synchronised cells were analysed as before (figure 6). A dramatic
increase in p21Waf1/Cip1 mRNA and protein expression was observed
in panobinostat treated cells that was not observed in the control
population. The timing of the upregulation of p21Waf1/Cip1 was of
particular significance. p21Waf1/Cip1 mRNA was double that observed
in control cells by 2 hours and increased 10-fold by 4 h. More
www.nature.com/scientificreports
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Figure 1 | Analysis of panobinostat-induced growth arrest. (A) FaDu cells were synchronised by double thymidine block and released in medium
containing 100 nM panobinostat or excipient control. Cells were harvested at the indicated times post release, fixed and stained with propidium iodide
before analysis by flow cytometry. The histograms represent propidium iodide fluorescence versus counts. (B) The proportion of cells in G1, S, or G2/M
phases from cells synchronised by double thymidine block (blue) and 8, 10 and 12 hours post release with (red) or without (green) 100 nM panobinostat
was calculated using ModFit LT 3.0 software (Verity Software House). The data represent the mean and standard deviation of at least 5 independent
experiments. (C) Cells were fixed and stained with propidium iodide (left panel) and a combination of propidium iodide and Alexa 488 conjugated anti-
phospho-histone H3 antibody (right panel). The data shown are from asynchronously growing cells and are representative of data collected at all time
points post release. (D) The percentage ofmitotic cells post release from a double thymidine block was calculated using Summit software (Dako) from the
phos-histone-H3 positive population of cells.
www.nature.com/scientificreports
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importantly, p21Waf1/Cip1 protein increased minimally by 4 h post
release (1.2-fold) and significantly (3-fold) at 8 h post release in
panobinostat treated cells whereas no increase in p21Waf1/Cip1 protein
was observed in control treated cells (figure 6C).
p21Waf1/Cip1 protein binds to the transcriptional activator E2F1 and
prevents E2F-dependent activation of the PLK1 promoter26. In
addition, the PLK1 and Cyclin B1 promoters are positively regulated
by E2F family members28,29. Therefore, we determined the effect of
panobinostat treatment on the expression of E2F family members in
synchronised cells (figure 7A). mRNA expression of all E2Fs tested is
reduced following treatment with panobinostat, with the greatest
effect on E2F3, which was repressed at least 2-fold compared to
Figure 2 | Reduced mitotic entry and mitotic abnormalities caused by panobinostat. FaDu cells were synchronised by double thymidine block and
released in medium containing 100 nM panobinostat or excipient control. (A) Cells were harvested at the indicated times post release and metaphase
spreads prepared. The percentage of metaphases was scored for each total cell population (n. 200). The data shown represents the mean and standard
deviation of each sample. (B) 9 hours post release, cells were fixed and stainedwith anti-a-tubulin antibody (green) and theDNA stainedwithDAPI (blue
and grey). Cells were visualised using an Axiovert 200 (Zeiss) microscope fitted with a 633 objective and images were captured using a Camera Hall 100
and the Applied Spectral Imaging software. The top panel shows representative images of mitotic cells in excipient control. Normal chromosome
congression atmetaphase and chromosome segregation at anaphase is observed. Themiddle panel shows representative images ofmetaphase cells treated
with panobinostat. Failure of chromosome congression (non-aligned chromosomes) is common in these cells. The lower panel shows a representative
image of a cell that has progressed to anaphase, showing lagging chromosomes (left DNA, middle a-tubulin and right merge). (C) The percentage of
mitotic cells and micronuclei in control (n5 126) or panobinostat treated (n5 131) cell populations was determined by microscopic analysis. The data
shown represent the mean and standard deviation for each sample. (D) The mitotic cells in control or panobinostat treated samples were scored for
various phenotypes as indicated in the bar chart and expressed as a percentage of the number ofmitotic cells counted. The data shown represent themean
and standard deviation for each sample.
www.nature.com/scientificreports
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control cells at 4 h post release. However, no significant reduction in
the protein levels of E2F1, E2F2 and E2F3 were observed by western
blot (data not shown). To explore the possibility that treatment with
panobinostat results in reduced association of the activating E2F
family members, E2Fs 1, 2 and 3, with the PLK1 and Cyclin B1
promoters and therefore loss of G2-specific activation of PLK1 and
Cyclin B1 expression, wemeasured association of these proteins with
the endogenous PLK1 and Cyclin B1 promoters by ChIP assay.
Treatment of cells with panobinostat for 6 h caused a dramatic
reduction in the association of E2F1 with both the PLK1 and
Cyclin B1 promoters (figures 7B and C). In contrast, E2F2 and
E2F3 were detected at both promoters at similar levels in control
and panobinostat treated cells.
Discussion
We and others have shown that panobinostat results in a cell cycle
arrest at G2/M20–22,30. The use of synchronised cell populations has
now enabled us to show definitively that the cells progress through S
phase with normal kinetics, followed by a significant delay at the G2
checkpoint and decreased mitotic entry. Cells that eventually enter
mitosis display significant abnormalities such as misaligned and lag-
ging chromosomes. Live cell imaging confirms that successful com-
pletion of mitosis in the presence of panobinostat is a rare event. The
experiments presented here have been carried out primarily in FaDu
cells, but the G2 arrest and changes in Plk1 and Cyclin B1 expression
following panobinostat treatment of synchronised cells have been
confirmed in UMSCC-1 and UMSCC-47 (20 and supplementary fig-
ures 1, 2 and 3), demonstrating that the G2 arrest caused by panobi-
nostat treatment observed in our studies is not specific to a particular
cell line. It is interesting to note that FaDu and UMSCC-1 cells are
HPV negative while UMSCC-47 cells are HPV positive, indicating
that the HPV status of the cells used in these experiment does not
affect the response to panobinostat.
It should be noted that our data are in contrast to a study by
Pettazzoni et al.21, which demonstrates an increase in histone H3
acetylation and phosphorylation at serine 10 following treatment
with panobinostat. While we did not specifically look at acetylation
of histone H3, the study by Pettazzoni et al. indicates that phosphor-
ylation at serine 10 is not affected by increased acetylation, indicating
that increased acetylation is not responsible for the loss of histoneH3
phosphorylation in our study (figure 1). Pettazzoni et al. also show an
increase in mitotic cells, normal Cyclin B1 protein expression and a
subtle decrease in Cdc2 phosphorylation at threonine 14 and tyro-
sine 15 in an asynchronous population following treatment with
panobinostat. From these experiments, it was concluded that pano-
binostat treatment pushes cells into mitosis, increasing the propor-
tion of cells at G2/M, followed by subsequent mitotic failure resulting
in cell death. These experiments were performed in prostate cancer
cells (LNCaP, DU145 and PC3) and while this difference alone could
account for the differential response to panobinostat treatment, all of
the experiments reported by Pettazzoni et al. were also performed at
low concentrations of panobinostat (10 nM). Indeed, a study by
Brazelle et al.22 in which various non-small cell lung cancer cells were
treatedwith 40 nMpanobinostat documented aG2/M arrest but also
noted a subtle increase in the phosphorylation of histoneH3 at serine
10 and an increase in multinucleated cells that indicates mitotic
catastrophe. It is possible that different cell types respond differently
to panobinostat exposure with either arrest of the cells prior to
mitotic entry (our study), ormitotic catastrophe due to inappropriate
mitotic entry21,22, or that different effects on the cell cycle may be
caused by different concentrations of drug used. In order to address
this question, we have carried out an experiment in which synchro-
nized FaDu cells were treated with 25 nM panobinostat and progres-
sion through the cell cycle compared to cells in excipient control or
100 nM panobinostat (supplementary figure 4). These experiments
show that in agreement with the experiments presented in Figures 1–
3, cells in excipient control pass through the S, G2 and mitotic
checkpoints normally and cells treated with 100 nM panobinostat
are almost completely arrested at the G2/M peak of the flow analysis
with minimal slippage through mitosis and into G1. However, cells
released into medium containing 25 nM panobinostat pass through
mitosis more frequently and by 12 hours post release, an almost
100% increase in G1 cells is observed when compared to cells treated
with 100 nM panobinostat (12.39% G1 with 100 nM panobinostat
compared to 23.12% G1 cells with 25 nM panobinostat). It will be
Figure 3 | Analysis of mitotic entry by live cell imaging. Cells growing in glass bottom dishes were synchronised by double thymidine block and released
in panobinostat or excipient control medium. 3 hours following release, cells were placed in a heated chamber and imaged using a 203 objective every 2
minutes. The representative images shown were taken at the stated time points following release.
www.nature.com/scientificreports
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interesting to determine whether other cells derived from HNSCC
behave in the same way as prostate and lung cancer cells at low dose
panobinostat and rather than arresting at G2, pass through this
checkpoint and into mitosis with catastrophic consequences. The
potential differential effects with varying panobinostat concentration
are likely to be very important in the clinical use of panobinostat and
should be taken into consideration when designing new clinical
trials. During a phase I clinical trial in which intravenous panobino-
stat was administered, it was demonstrated that the half-life of pano-
binostat is in the order of 10–14 hours and serum concentrations of
400–700 nM are achievable at doses that are well tolerated31. These
Figure 4 | Reduction of G2-specific Plk1 expression following
panobinostat treatment. FaDu cells were synchronised by double
thymidine block and released inmedium containing 100 nMpanobinostat
or excipient control. Cells were harvested at the stated time points post
release and RNA (A) and protein (B and C) harvested as described in the
materials and methods. (A) PLK1 mRNA expression was assessed by qRT-
PCR. The data shown represent PLK1 mRNA levels normalised to 0 hour
time point and are shown as the mean and standard deviation of three
independent experiments. (B) 60 mg protein from each extract was
separated by SDS-PAGE on two separate gels run using identical
conditions. The upper panel was probed with Plk1 antibody and the lower
panel probed with b-actin antibody. Full-length digital images of these
western blots can be viewed in the supplementary information
(supplementary figure 5). (C) Plk1 protein levels from three independent
experiments were quantified using ImageGauge v4.21 software and
normalised to b-actin levels from the same experiment. The data shown
represent the mean and standard deviation.
Figure 5 | Reduction of G2-specific Cyclin B1 expression following
panobinostat treatment. FaDu cells were synchronised by double
thymidine block and released inmedium containing 100 nMpanobinostat
or excipient control. Cells were harvested at the stated time points post
release and RNA (A) and protein (B and C) harvested as described in the
materials and methods. (A) Cyclin B1 mRNA expression was assessed by
qRT-PCR. The data shown represent Cyclin B1mRNA levels normalised to
0 hour time point and are shown as the mean and standard deviation of
three independent experiments. (B) 60 mg protein from each extract was
separated by SDS-PAGE on two separate gels that were run using identical
conditions. Cyclin B1 (upper panel) and b-actin (lower panel) protein
levels were assessed by Western blot. Full-length digital images of these
western blots can be viewed in the supplementary information
(supplementary figure 5). (C) Cyclin B1 protein levels from three
independent experiments were quantified using ImageGauge v4.21
software and normalised to b-actin levels from the same experiment. The
data shown represent the mean and standard deviation.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2640 | DOI: 10.1038/srep02640 6
data indicate that the experiments carried out in this study have
relevance to the clinical use of panobinostat and that the dose admi-
nistered needs to be carefully assessed for optimal performance of
this drug in treating different malignancies.
In agreement with our study, cells treated with various HDACi
(although not panobinostat) were delayed at the G2 checkpoint and
progressed slowly through mitosis32. In this study, cells arrested for
an extended period in prometaphase with infrequent progression to
metaphase and anaphase.Mitotic defects similar to those observed in
our study were also demonstrated along with a significant increase in
transit time through mitosis. Interestingly, combined treatment of
cells with the HDACi suberohydroxamic acid (SBHA) and nocoda-
zole, to inactivate the spindle assembly checkpoint, resulted in
delayed mitotic entry followed by mitotic exit with similar kinetics
to untreated cells. This provides evidence that SBHA treated cells
override the spindle assembly checkpoint and exit mitosis with aber-
rant chromosome segregation.
It is well documented that p21Waf1/Cip1 protein expression is
induced by numerous HDACi (reviewed by33). The activation of
p21Waf1/Cip1 by various HDACi has been demonstrated in p53 null
ormutant cells such as the FaDu cells used in this study, which have a
homozygousmutation in p53 at codon 248 that results in an arginine
to leucine substitution rendering p53 incapable of activating tran-
scription from a variety of promoters34,35. The activation of
p21Waf1/Cip1 by HDACi in cells with mutated or null p53 protein has
been studied and in this context activation of p21Waf1/Cip1 requires
acetylation of H2A.X at the p21 promoter36. p21Waf1/Cip1 has pleio-
tropic effects on cell cycle progression, mediated primarily by asso-
ciation with and inhibition of Cyclin dependent kinases (CDKs)
leading to G1, S or G2-specific growth arrest. The kinetics of the
increase in p21Waf1/Cip1 protein expression observed in this study
are in agreement with that seen by Maiso et al. who document an
increase in p21Waf1/Cip1 protein 3 h following treatment with 100 nM
panobinostat24. We speculated that this dramatic increase in
p21Waf1/Cip1 protein levels, which coincides with mitotic entry in our
experimental system results in the repression of other p21Waf1/Cip1
regulated genes that are essential for mitotic entry and exit, although
why a co-incident G1 arrest is not observed in asynchronously grow-
ing cells from HNSCC treated with panobinostat has not been
resolved. It is worth noting that p21Waf1/Cip1 can inactivate prolif-
erating cell nuclear antigen (PCNA) thereby inhibiting PCNA-
dependent DNA replication37. However, DNA replication appears
to progress normally in the presence of panobinostat leading us to
conclude that this does not contribute to the growth arrest caused by
panobinostat in our experiments.
We attribute the panobinostat-mediated G2 delay and down-
stream mitotic defects to aberrant Plk1 and Cyclin B1 expression
since reduction of Plk1 expression by RNA interference produces
similar mitotic and cytokinesis defects, and Cyclin B1 knockdown
causes a G2 delay and slower mitotic transition with similar abnor-
malities to those observed in this study38,39. It has been demonstrated
that both the PLK1 and Cyclin B1 promoters are repressed by the
over expression of p21Waf1/Cip1 25–27. A role for the E2F family of tran-
scription factors in the positive regulation of PLK1 expression has
also been reported. E2Fs 1, 2 and 3 act directly on the PLK1 promoter
to stimulate transcription activation28. Furthermore, p21Waf1/Cip1 has
been shown to control the activity of E2F1 and prevent E2F1-
dependent activation of promoters that contain E2F binding sites.
This is at least in part independent of Retinoblastoma (Rb) protein
function and is reported to be through a direct interaction between
p21Waf1/Cip1 and E2F140. We have assessed the occupancy of the endo-
genous Plk1 and Cyclin B1 promoters by E2Fs 1, 2 and 3 by ChIP
assay and show a dramatic and significant decrease in E2F1 protein
associated with both of these promoters. This was somewhat surpris-
ing since the mRNA expression of E2F1 is least affected by treatment
with panobinostat, however, the PLK1 promoter at least is most
responsive to E2F128 and small changes in protein levels or activity
could have dramatic effects on the expression of downstream acti-
vated genes. Nonetheless, these findings support our hypothesis that
panobinostat-induced p21Waf1/Cip1 protein expression results in the
E2F1 dependent repression of G2-specific genes. Whether this is
regulated by post-translational modification including acetylation
Figure 6 | Panobinostat induced p21Waf1/Cip1 expression. FaDu cells were
synchronised by double thymidine block and released in medium
containing 100 nM panobinostat or excipient control. Cells were
harvested at the stated time points post release andRNA (A) and protein (B
andC) harvested as described in thematerials andmethods. (A) p21Waf1/Cip1
mRNA expression was assessed by qRT-PCR. The data shown represent
p21Waf1/Cip1 mRNA levels normalised to 0 hour time point and are shown as
the mean and standard deviation of three independent experiments.
(B) 60 mg protein from each extract was separated by SDS-PAGE on two
separate gels runs using identical conditions and p21Waf1/Cip1 (upper panel)
and b-actin (lower panel) protein levels were assessed by Western blot.
Full-length digital images of these western blots can be viewed in the
supplementary information (supplementary figure 5). (C) p21Waf1/Cip1
protein levels from three independent experiments were quantified using
ImageGauge v4.21 software and normalised to b-actin levels from the same
experiment. The data shown represent the mean and standard deviation.
www.nature.com/scientificreports
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of E2F1 or p21Waf1/Cip1, changes in sub-cellular localization of E2F1, or
direct interaction of p21Waf1/Cip1 and E2F1 following panobinostat
treatment are hypotheses we are currently exploring.
Our study provides evidence that panobinostat treatment causes a
G2 delay and abnormal mitotic progression through p21Waf1/Cip1-
mediated suppression of E2F1 activation of Cyclin B1 and PLK1
expression, which are required for passage through the G2 check-
point and normal mitotic transition. Our findings will inform future
clinical studies designed to explore how panobinostat might be used
in combination with other therapies to improve outcomes in patients
with epithelial tumours, for example, through its sequential delivery
with other mitosis blocking agents such as taxanes. Given that there
is now considerable interest in exploring how epigenetic priming
may make cancer cells more sensitive to radiotherapy, there is a
compelling case for adding panobinostat to the list of HDAC inhi-
bitors currently under evaluation as potential modulators of radi-
ation sensitivity41–43. We are currently addressing these possibilities
to optimise the use of panobinostat in future pre-clinical trials
Figure 7 | Loss of E2F1 recruitment to the Plk1 and Cyclin B1 promoters in response to panobinostat. (A) FaDu cells were synchronised by double
thymidine block and released in medium containing 100 nM panobinostat or excipient control. Cells were harvested at the stated time points post
release and RNA. E2F1, E2F2, E2F3 and E2F5mRNA expression was assessed by qRT-PCR. The data shown represent mRNA levels normalised to 0 hour
time point and are shown as themean and standard deviation of three independent experiments. (B and C)Asynchronous FaDu cells were incubated with
100 nM panobinostat or excipient control for 12 hours and crosslinked. Chromatin was then extracted and sheared and clarified chromatin preparations
were immunoprecipitated with anti-FLAG (negative), E2F1, E2F2 or E2F3 antibody. The percentage of bound PLK1 promoter (B) or Cyclin B1 promoter
(C) was then assessed by qRT-PCR and shown as the mean and standard deviation of three independent experiments.
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designed to determine whether these combinations would be more
effective and less toxic than current regimens.
Methods
Cell culture. FaDu cells (ATCC #HTB-43), are an HPV negative cell line derived
from a squamous cell carcinoma of the hypopharynx, were cultured at 37uC, 5% CO2
in RPMI 1640, containing 10% fetal bovine serum and 1 mM sodium pyruvate.
UMSCC-1 cells originate from a tumour from the floor of themouth in amale patient
and are HPV negative. UMSCC-47 cells are derived from a tumour of the lateral
tongue in a male patient and are HPV16 positive. Both of these cell lines were
approved and cultured as previously described23,44. Cells are routinely tested for
mycoplasma infection using a MycoAlert kit (Lonza).
Panobinostat. Panobinostat (LBH589; obtained from Peter Atadja, Novartis) was
dissolved in d5W to 4.6 mM, the stock was then diluted to 100 nM in culture
medium. Excipient control was prepared at the same d5W dilution.
Cell cycle synchronisation. 2 mM thymidine was added to 50% confluent cells,
which were incubated for 15 h. Cells were then reseeded at 23 106 cells/10 cm plate
and left to recover for 12 h. 2 mM thymidine was added again and the cells were
incubated for 14 h. Cells were either harvested immediately (0 h) or released in
medium containing panobinostat or D5W alone (control) and harvested at the
indicated times.
Flow cytometry. Cells were trypsinised and fixed in 1 ml of ice cold 70% ethanol.
Cells were then washed in 1% BSA/PBS, and incubated for 30 min in BSA/PBS
containing 50 mg/ml propidium iodide and 20 mg/ml RNase A. Samples were
analysed using a FACSCanto II (Becton Dickinson) flow cytometer equipped with a
488 nm laser. Emission was detected using a 585/42 nm band pass filter. Data were
analysed using ModFit LT 3.0 software (Verity Software House).
For immunofluorescent staining of phosphorylated histone H3, cells were fixed
with 1% formaldehyde in PBS before fixing in ethanol. Cells were resuspended in 1%
BSA/PBS containing with Alexa 488-conjugated anti-phospho-histone H3 (Ser10)
antibody (Cell Signaling 9708) and incubated for 1 h before staining with propidium
iodide. Cells were analysed as described above with the additional measurement of
fluorescence emission using 530/30 nm band pass filter.
Chromosome analysis and immunofluorescence. Cells were synchronised and
released into culture medium, followed by standard hypotonic treatment and fixation
in methanol/acetic acid. For immunofluorescence, panobinostat treated and control
cells were grown on glass coverslips and fixed in ice cold methanol for 10 min. Cells
were then incubated with 5% goat serum followed by incubation with mouse anti a-
tubulin (DM1A, Sigma; 151000) and detection with anti mouse Alexa-488
(Invitrogen; 151000). The cells were counterstained with DAPI and imaged with an
Axiovert 200 microscope (Zeiss) with an oil immersion lens (603, NA 1.35).
Live cell imaging. Time-lapse microscopy was performed with a 203/0.5 NA phase
contrast objective on an inverted microscope (NIKON TE2000-E) at 37uC and 5%
CO2. Red LED illumination (CoolLED) and a CCD camera (Andor iXon), controlled
by Micro-Manager software were used to acquire one image every 2 min45.
RNA extraction. Total RNA was isolated using TRIzol (Invitrogen). RNA was
quantified using a Nanodrop 2000 and quality was confirmed using an Agilent
Bioanalyzer and Agilent RNA 6000 Nanochips. All had RNA Integrity Numbers
$9.2.
Quantitative real time PCR. qRT-PCR was performed using the Taqman RNA-to-
CT 1-Step Kit (Applied Biosystems) and Gene Expression Assays; CDKN1A (p21)
(Hs00355782_m1), PLK1 (Hs00153444), CCNB1 (Cyclin B1) (Hs01030097_m1) and
GAPDH (Hs99999905_m1). Individual reactions were set up in triplicate from a
master mix (32 ml Taqman 23 RT-PCRmix, 3.2 ml RNA (100 ng/ml), 3.2 ml primers
(18 mM), 1.6 ml enzyme, 24 ml water). qRT-PCRmeasurements were performed on a
StepOnePlus RT-PCR instrument (Applied Biosystems), using the following
program: 48uC for 15 min, 95uC for 10 min and 40 cycles of 95uC for 15 s, 60uC for
1 min. The comparative threshold (CT) was determined for each gene as the average
of three separate experiments.
Normalized values (DCT) were calculated by subtracting the CT for GAPDH from
the CT of each gene. DDCT values for each time point/condition was generated by
subtracting theDCT for each time sample from theDCT of the 0 hour sample for each
experiment. The power (2, DDCT) was used to determine the fold change of the gene
of interest in each sample relative to the 0 hour sample for each experiment.
Protein sample preparation and quantification. Cells were lysed in ice cold RIPA
buffer (1%NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 2 mMEDTA, 25 mMTris-
HCl, pH 7.5 containing 13 Complete protease inhibitors (Roche)). The genomic
DNA was sheared by passing the lysate 33 through a 21-gauge needle and lysates
cleared by high-speed centrifugation at 4uC. Protein concentration was determined
by BCA assay (Pierce).
Western blotting. Membranes were probed with anti-Plk1 antibody (Abcam
Ab70697, 151000), p21Waf1/Cip1 (Dako SX118, 151000), Cyclin B1 (Santa Cruz H-433,
151000) or H2AX (Bethyl A300-081, 151000) and either anti-mouse or anti-rabbit
secondary antibody conjugated to HRP (Jackson Laboratories. 1510,000). Detection
was performed using Supersignal Dura (ThermoFisher Scientific) and images
captured on a Fujifilm LAS3000 digital detection system. Protein levels were
quantified using ImageGauge.
Chromatin immunoprecipitation.Cells were treated with 100 nM panobinostat for
6 h before crosslinking with 1% formaldehyde for 30 min. 120 mM Glycine (final
concentration) was added for 5 min before washing with PBS. 300 ml lysis buffer
(50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS and 13 protease inhibitor
cocktail) was added and the cells harvested by scraping. Samples were sonicated and
centrifuged at 14,000 rpm, 4uC. Supernatants were diluted 10-fold in ChIP dilution
buffer (16.7 mM Tris-HCl, pH 8.0, 0.01% SDS, 1.1% Trition-X-100, 1.2 mM EDTA,
167 mMNaCl, 13 protease inhibitor cocktail) and to 1 ml of each sample, 10 ml 50%
slurry Protein Gmagnetic sepharose beads (Invitrogen) and 2 mg of antibody (FLAG
M2 (Sigma, F1804), E2F1 (Abcam, ab94888), E2F2 (Abcam, ab65222) or E2F3
(Abcam, ab74180)) was added. Following incubation at 4uC for 2 h with nutation,
beads were washed in low salt buffer (20 mM Tris-HCl, pH 8.0, 150 mMNaCl, 0.1%
SDS, 2 mM EDTA, 0.5% Triton-X-100), high salt buffer (20 mM Tris-HCl, pH 8.0,
250 mM LiCl, 1 mM EDTA, 0.5% NP40, 1% Na-deoxycholate), and TE (10 mM
Tris-HCl, pH 8.0, 1 mM EDTA). 100 ml elution buffer (1% SDS, 100 mMNaHCO3)
was then added to each sample and incubated for 30 min. NaCl concentration was
made up to 200 mM and the samples incubated overnight at 65uC. 10 mM EDTA,
40 mM Tris-HCl, pH 8.0 (final concentration) and RNase A (0.25 mg/ml) were
added to each sample followed by incubation at 37uC for 1 h. Proteinase K (50 mg/ml
final) was added and the samples incubated at 50uC for 1 h. The DNA was extracted
with phenol-chloroform and ethanol precipitated. Pellets were resuspended in 20 ml
water.
For qRT-PCR analysis a 10-fold serial dilution of input samples was created and
1 ml of each sample added to 24 ml Brilliant II SyBr Green mastermix (Agilent
Technologies) containing 10 pmol of each primer for amplification of the PLK1
promoter (forward: 59-GGTTTGGTTTCCCAGGCTAG-39, reverse: 59-GCTG-
GGAACGTTACAAAAGC-39)28 or the Cyclin B1 promoter (forward: 59-CGAT-
CGCCCTGGAAACGCATTC-39, reverse 59-CCAGCAGCCACCAACAG-
CCGTTC-39)46. DNAwas amplified by incubation at 95uC for 10 min followed by 40
cycles of 95uC for 30 s, 57uC for 30 s and 72uC for 1 min. Ct values for each sample
were calculated at a constant threshold and expressed as fold change over negative
control.
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